006280 — GC Biopharma Income Statement
0.000.00%
Last trade - 00:00- KR₩1tn
- KR₩3tn
- KR₩2tn
- 31
- 45
- 60
- 41
Annual income statement for GC Biopharma, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,504,115 | 1,537,826 | 1,711,313 | 1,626,644 | 1,679,892 |
| Cost of Revenue | |||||
| Gross Profit | 440,627 | 520,593 | 581,804 | 484,633 | 481,932 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1,403,645 | 1,455,901 | 1,589,582 | 1,592,208 | 1,665,361 |
| Operating Profit | 100,471 | 81,925 | 121,731 | 34,436 | 14,531 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 104,474 | 172,559 | 85,728 | -27,135 | -41,110 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 89,108 | 136,950 | 69,415 | -19,809 | -42,637 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 81,049 | 123,212 | 65,453 | -26,632 | -26,280 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 81,049 | 123,212 | 65,453 | -26,632 | -26,280 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 3,323 | 10,309 | 2,850 | -2,167 | -1,087 |
| Dividends per Share |